Global CD47 Targeting Therapeutics Market

Report ID : 1290 | Published : 2022-06-29 | Pages: | Format: PDF/EXCEL

CD47 is immunoglobulin and supramolecular complex composed of integrins, G protein, and cholesterol. It mediates a series of processes such as cell proliferation, migration, phagocytosis, apoptosis, immune homeostasis, and inhibition of NO signalling. In recent years, CD47 also called the “don’t eat me” signal, has been highly expressed on the surface of various cancers, initiating an inhibitory signalling pathway that prevents cancer cells from phagocytosis by macrophages. 

The factors driving the growth of the CD47 targeting therapeutics market include the rising developments in the CD47-targeting anti-cancer therapies, growing demand for cost-efficient cancer treatments, increasing government initiatives for cancer awareness, and R&D initiatives by market players for launching effective cancer therapies, and the growing number of cancer cases worldwide. According to the NCI (National Cancer Institute), cancer is among the leading causes of death worldwide. By 2040, more cancer cases are expected to rise to 29.5 million per year and cancer-related deaths to 16.4 million. Recently, the American FDA has granted orphan drug designation ("ODD") to ALX Oncology's next-generation CD47 blocker ‘evorpacept’ for treating patients with gastroesophageal junction cancer and gastric cancer. Thus, the increasing prevalence of cancer is projected to surge the demand for advanced cancer therapies to treat cancer patients effectively, which will likely fuel the market growth over the forecast period. However, the high R&D cost of target therapies and side effects associated with these therapies are expected to hamper the market’s growth in the coming years.  

The CD47 targeting therapeutics market is classified based on target disease indication, type of molecule, and region. The target disease indication, segment the market into acute myeloid leukemia, non-hodgkin lymphoma, colorectal cancer, diffuse large B-cell lymphoma, myelodysplastic syndromes, non-small cell lung cancers, ovarian epithelial cancer, oral mucositis, small cell lung cancers, and other disease indications. The acute myeloid leukaemia segment is anticipated to proliferate over the forecast period owing to the increased CD47 expression on human AML. The market is grouped into biologics and small molecules by type of molecule. Due to its increasing therapeutic applications, the biologics segment is expected to witness significant growth during the forecast years. Regionally, the market is considered across North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa.

North America is likely to witness the highest growth during the forecast period due to the high prevalence of cancer, growing demand for CD47 therapeutic products, and the increasing approvals for immunoglobulins.

Significant the key players operating in the CD47 targeting therapeutics market are Conjupro biotherapeutics (US), EpicentRx (US), Forty Seven (US), ImmuneOncia Therapeutics (Korea), ImmuneOnco Biopharmaceuticals (China), Innovent Biologics (China), KAHR Medical (Israel), Light Chain Bioscience (Switzerland), Morphiex (US), Trillium Therapeutics (Canada), TG Therapeutics, Adagene, Alector, Inc., Apmonia Therapeutics, I-MAB Biopharma Co., Ltd., QLSF Biotherapeutics Inc., Phanes Therapeutics, Inc., Bio-Thera Solutions, others.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global CD47 Targeting Therapeutics Market Snapshot

Chapter 4. Global CD47 Targeting Therapeutics Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Clinical Trial/Pipeline Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 2: By Target Disease Indication Estimates & Trend Analysis

5.1. By Target Disease Indication & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Target Disease Indication:

5.2.1. Acute Myeloid Leukemia

5.2.2. Non-Hodgkin Lymphoma

5.2.3. Colorectal Cancer

5.2.4. Diffuse Large B-cell Lymphoma

5.2.5. Myelodysplastic Syndromes

5.2.6. Non-Small Cell Lung Cancers

5.2.7. Ovarian Epithelial Cancer

5.2.8. Oral Muscositis

5.2.9. Small Cell Lung Cancers

Chapter 6. Market Segmentation 4: By Molecules Estimates & Trend Analysis

6.1. By Molecules & Market Share, 2020& 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Molecules:

6.2.1. Biologics

6.2.2. Small Molecule

Chapter 7. CD47 Targeting Therapeutics Market Segmentation 5: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts By Target Disease Indication, 2019-2030

7.1.2. North America CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts By Types, 2019-2030

7.1.3. North America CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by Molecules, 2019-2030

7.1.4. North America CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by country, 2019-2030

7.2. Europe

7.2.1. Europe CD47 Targeting Therapeutics Market revenue (US$ Million) By Target Disease Indication, 2019-2030

7.2.2. Europe CD47 Targeting Therapeutics Market revenue (US$ Million) By Types, 2019-2030

7.2.3. Europe CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by Molecules, 2019-2030

7.2.4. Europe CD47 Targeting Therapeutics Market revenue (US$ Million) by country, 2019-2030

7.3. Asia Pacific

7.3.1. Asia Pacific CD47 Targeting Therapeutics Market revenue (US$ Million) By Target Disease Indication, 2019-2030

7.3.2. Asia Pacific CD47 Targeting Therapeutics Market revenue (US$ Million) By Types, 2019-2030

7.3.3. Asia Pacific CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by Molecules, 2019-2030

7.3.4. Asia Pacific CD47 Targeting Therapeutics Market revenue (US$ Million) by country, 2019-2030

7.4. Latin America

7.4.1. Latin America CD47 Targeting Therapeutics Market revenue (US$ Million) By Target Disease Indication, 2019-2030

7.4.2. Latin America CD47 Targeting Therapeutics Market revenue (US$ Million) By Types, 2019-2030

7.4.3. Latin America CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by Molecules, 2019-2030

7.4.4. Latin America CD47 Targeting Therapeutics Market revenue (US$ Million) by country, 2019-2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa CD47 Targeting Therapeutics Market revenue (US$ Million) By Target Disease Indication, 2019-2030

7.5.2. Middle East & Africa CD47 Targeting Therapeutics Market revenue (US$ Million) By Types, 2019-2030

7.5.3. Middle East & Africa CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by Molecules, 2019-2030

7.5.4. Middle East & Africa CD47 Targeting Therapeutics Market revenue (US$ Million) by country, 2019-2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles 

8.2.1. Abpro

8.2.2. ALX Oncology

8.2.3. Apmonia Therapeutics

8.2.4. Arch Oncology

8.2.5. Aurigene

8.2.6. Bristol Myers Squibb

8.2.7. Conjupro biotherapeutics

8.2.8. EpicentRx

8.2.9. Forty Seven

8.2.10. ImmuneOncia Therapeutics

8.2.11. ImmuneOnco Biopharmaceuticals

8.2.12. Innovent Biologics

8.2.13. KAHR Medical

8.2.14. Light Chain Bioscience

8.2.15. Morphiex

8.2.16. Trillium Therapeutics

8.2.17. TG Therapeutics

8.2.18. Adagene

8.2.19. Alector, Inc.

8.2.20. Apmonia Therapeutics

8.2.21. I-MAB Biopharma Co., Ltd.

8.2.22. QLSF Biotherapeutics Inc.

8.2.23. Phanes Therapeutics, Inc.

8.2.24. Bio-Thera Solutions

8.2.25. Other Prominent Players

Global CD47 Targeting Therapeutics Market, by Target Disease Indication, 2022-2030 (Value US$ Mn)

  • Acute Myeloid Leukemia
  • Non-Hodgkin Lymphoma
  • Colorectal Cancer
  • Diffuse Large B-cell Lymphoma
  • Myelodysplastic Syndromes
  • Non-Small Cell Lung Cancers
  • Ovarian Epithelial Cancer
  • Oral mucositis
  • Small Cell Lung Cancers
  • Other Diseases Indications

Global CD47 Targeting Therapeutics Market, by Type of Molecule, 2022-2030 (Value US$ Mn)

  • Biologics
  • Small Molecule

Global CD47 Targeting Therapeutics Market, by Region, 2022-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

 

Competitive Landscape

  • Abpro
  • ALX Oncology
  • Apmonia Therapeutics
  • Arch Oncology
  • Aurigene
  • Bristol Myers Squibb
  • Conjupro biotherapeutics
  • EpicentRx
  • Forty Seven
  • ImmuneOncia Therapeutics
  • ImmuneOnco Biopharmaceuticals
  • Innovent Biologics
  • KAHR Medical
  • Light Chain Bioscience
  • Morphiex
  • Trillium Therapeutics
  • TG Therapeutics
  • Adagene
  • Alector, Inc.
  • Apmonia Therapeutics
  • I-MAB Biopharma Co., Ltd.
  • QLSF Biotherapeutics Inc.
  • Phanes Therapeutics, Inc.
  • Bio-Thera Solutions

Other Prominent Players

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?

Frequently Asked Questions

Who are the Key Players in the CD47 Targeting Therapeutics Market?
Our Clients